Cardioversion In Patients Research Articles

Predictive Value of N-Terminal Pro B-Type Natriuretic Peptide for Short-Term Outcome of Cardioversion in Patients with First-Diagnosed or Paroxysmal Atrial Fibrillation Presenting to the Emergency Department.

Background: Atrial fibrillation (AF) is a common arrhythmia in the emergency department (ED). We investigated the role of N-terminal pro b-type natriuretic peptide (NT-proBNP) in predicting both the outcome of AF cardioversion and the risk of AF recurrence or persistence on the 8th (D8) and 30th (D30) day post-cardioversion. Methods: This prospective, observational study evaluated patients with recent-onset AF, managed by either pharmacological (PC) or electrical cardioversion (EC) in the ED. Patients were treated either immediately or electively after 3 weeks of anticoagulation. NT-proBNP assessments were performed prior to cardioversion. Results: Of the 148 patients enrolled, 56% had paroxysmal AF, 85% underwent immediate cardioversion and 72% received EC. Successful cardioversion to sinus rhythm (SR) was achieved in 85% of patients. Patients with successful cardioversion and those who remained free from AF on D8 had lower NT-proBNP levels compared to patients with failed cardioversion or with AF recurrence or persistence on D8 [day of cardioversion, D0: SR vs. non-SR, 387 (127-1095) pg/mL vs. 1262 (595-2295), p = 0.004; D8: SR vs. non-SR, 370 (127-1095) vs. 1366 (718-2295), p = 0.002]. In multivariate analysis, higher logNT-proBNP was associated with higher risk of cardioversion failure [OR, 95%CI: 4.80 (1.58-14.55), p = 0.006] and AF recurrence or persistence on D8 [OR, 95%CI: 3.65 (1.06-12.59), p = 0.041]. ROC analysis confirmed the predictive ability of NT-proBNP for both outcomes (D0: AUC 0.735, p < 0.001; D8: AUC 0.761, p < 0.001). A cut-off value of NT-proBNP > 580 pg/mL was able to predict failure of AF conversion and occurrence of recurrent/persistent AF at D8. Conclusions: NT-proBNP is a promising biomarker for identifying patients presenting to the ED with recent-onset AF who run a greater risk of cardioversion failure and post-discharge AF recurrence/persistence in the immediate and short term.

Do current indices predict cardioversion success in patients with atrial fibrillation? A retrospective observational study

Abstract Objective Atrial fibrillation (AF) is one of the leading arrhythmias that causes serious complications. Our aim is to investigate the factors predicting the success of cardioversion in patients who underwent the procedure due to AF. Methods A total of 107 patients who underwent cardioversion were included in the study. Patients were divided into groups based on cardioversion success. Demographic, echocardiographic, and laboratory characteristics were compared between the groups. Results Hypertension and diabetes mellitus were more frequent in patients with successful cardioversion, but no statistically significant difference was found between the groups (p &gt; 0.05). The pre-procedure leukoglycemic index (LGI) was found to be higher in the successful cardioversion group. However, this difference was not statistically significant between the groups (p &gt; 0.05). Although the fibrosis-4 (FIB-4) index and systemic immune-inflammation index (SII) were numerically higher in the group with unsuccessful cardioversion, no statistically significant difference was observed between the groups (p &gt; 0.05). Echocardiographic parameters such as left atrial diameter and mitral regurgitation rate were higher in patients with successful cardioversion, but no significant difference was detected between the groups (p &gt; 0.05). Conclusion AF is a significant arrhythmia that may lead to high mortality and morbidity. Various scoring systems have been developed to predict cardioversion success. The LGI, FIB-4 index, and SII are potential predictors of cardioversion success. However, these parameters alone are insufficient to predict cardioversion success. Further large-scale randomized studies are needed to clarify the effectiveness of these parameters.

Abstract 4119189: Imaging practices prior to cardioversion in patients presenting post percutaneous left atrial appendage occlusion.

Background: Direct current cardioversion (DCCV) carries a risk for stroke in AF patients, for that reason there are guidelines for mitigating this risk in AF patients on oral anticoagulation (OAC). Meanwhile, no consensus on the best approach for cardioverting patients with an appendage occlusion device in situ. This led to a very wide variation in pre and post DCCV practices in these patients. Aims: We aim to explore different factors that might be associated with the variation seen in pre-DCCV imaging practices in patients presenting post- percutaneous LAAO. Methods: This was a multi-center retrospective cohort study of patients who received DCCV for AF or AFL during follow up after LAAO procedure within a single healthcare system from 2016-2024. Results: A total of 119 patients were included, there were more females 70 (59%), with more than half (64 (54%)) receiving a first-generation WATCHMAN™ 2.5, while the rest had WATCHMAN FLX™. Median age at presentation was 77 years (72,82), BMI of 31 kg/m 2 (26,37), average CHADSVASC score of 4.5 and HASBLED score of 3. A median duration of 10 months (3,21) between LAAO to presentation for DCCV . Forty-four (37%) patients had pre-DCCV imaging (imaging cohort). Number of males was significantly higher in the imaging cohort (24 (54.5%) vs 25 (33.3%), p=0.038), compared to those without imaging. There was a significant difference (p&lt;0.001) between the two cohorts in the location (center) where DCCV was done. The site with the highest number of pre-DCCV imaging cases had an equal gender ratio of patients presenting for DCCV. Patients who received imaging presented earlier (11.2 months vs 15.8 months, p=0.068) compared to those without imaging, though the difference was not significant. Between the two groups, there was no significant difference in OAC (VKA-antagonist/DOAC) usage prior to presentation (8 (18.6%) vs 12 (16.4%), P=0.9). There was no significant difference in baseline CHADSVASC score, HASBLED score, age, LVEF. Higher percentage of patients were discharged on OAC post DCCV in the imaging arm (13 (30.2%) vs 14 (19.4%), p=0.27), but the difference was non-significant. No Device related thrombus nor significant PDL was detected on imaging. Conclusion: There was male preference in providing pre-DCCV imaging for ruling out DRT. Location of care was also associated with the variation in pre-DCCV protocols. Additional research is needed to understand other factors associated with variation seen in pre-DCCV practices.

Atrial function after cardioversion in patients with persistent atrial fibrillation

Abstract Background After cardioversion for persistent atrial fibrillation (AF), restitution of normal left atrial (LA) function is said to need several days to recover. However, in previous studies, the evaluation of LA function was only used transesophageal or transthoracic echocardiography. During catheter ablation (CA) for AF, pulmonary venous (PV) blood flow can be measured accurately using an intracardiac echocardiogram (ICE). The atrial systolic PV regurgitation (PVa) wave measured by ICE is a good indicator of LA contractility because it reflects the active contraction of the LA. Purpose This study aims to investigate the LA function in the hyperacute phase and the factors which affect after cardioversion. Methods 40 AF patients (18 paroxysmal AF, 22 persistent AF) who underwent CA were enrolled. PVa wave was measured twice before RFCA and after the procedure using intracardiac ultrasound. Voltage map of the LV was obtained using the CARTO system at the end of the session, and the percentage of low voltage area which was determined area as less than 0.1mV in the mapped LA surface area (LVA%) was calculated. Results Preoperative PVa was 1.61 ± 0.09 m/sec in the paroxysmal AF group (PaAF), and no PVa was observed in the persistent AF group (PeAF). Postoperative PVa were comparable between PaAF (0.18±0.06 m/sec) and PeAF (0.18±0.07 m/sec). Then, the PeAF were divided into 2 groups based on LVA% in the anterior area, posterior area, and total LA area (cutoff 1,5 and 10%, respectively). In the anterior lower LVA% group, PVa were significantly increased (0.20 ± 0.07 m/sec) after defibrillation compared with the anterior higher LVA% group (0.14 ± 0.06 m/sec; P=0.02), whilst no difference was observed when it was divided in the posterior wall or overall. Conclusion Even in PeAF, LA function improves to the same degree as in the PaAF immediately after cardioversion, and the posterior wall LVA, including posterior wall isolation, may not affect LA function.

Ablation therapy following unsuccessful electrical cardioversion in patients with persistent atrial fibrillation

Electrical cardioversion (ECV) a widely utilized intervention for persistent atrial fibrillation (AF) aimed at restoring sinus rhythm. However, ECV can be ineffective, raising questions about subsequent treatment options. This study aimed to compare the outcomes of non-ablation therapy versus ablation therapy following unsuccessful ECV. A total of 125 consecutive patients with persistent AF who underwent unsuccessful ECV between November 2017 and August 2023 was included in this retrospective analysis. Of these, 51.2% received only medical therapy (non-ablation therapy group, n = 64), while 48.8% underwent AF ablation (ablation therapy group, n = 61). Various ablation methods were employed, including catheter and thoracoscopic ablation. Ablation therapy was associated with significantly better AF-free survival compared to non-ablation therapy [hazard ratio (HR), 0.37; 95% confidence interval (CI) 0.22–0.61; p < 0.01]. There was no difference of AF-free survival between catheter ablation and thoracoscopic ablation groups (HR 0.79, 95% CI 0.34–1.83; p = 0.58). AF duration > 5 year (HR 1.51; 95% CI 0.930–2.437; p = 0.10), BMI ≤ 25 kg/m2 (HR 1.61; 95% CI 1.004–2.581; p = 0.05) and diabetes (HR 2.38; 95% CI 0.902–6.266; p = 0.08) were considerable as predictor of AF recurrence. Ablation therapy following unsuccessful ECV was associated with maintaining sinus rhythm, regardless of the specific ablation method utilized.

Evaluation of Changes in Cardiac Troponin I Levels After Direct Current Cardioversion in Patients With Atrial Fibrillation.

Direct current cardioversion (DCCV) of atrial fibrillation (AF) is a procedure used to restore normal heart rhythm. Cardiac biomarkers, such as cardiac troponin I (cTnI), are elevated in situations where injury-myocardial cell necrosis is induced. The aim of the present study was to investigate the change in cTnIlevels, i.e., whether a myocardial injury is present, in patients with AF whose elective treatment was synchronized DCCV via a biphasic defibrillator. The study sample included 59 patientswho underwent synchronized DCCV for AF reversion. Measurement of cTnI before and after DCCV (one, three, and six hours) was performed by blood sampling and subsequent assay. It was observed that the value of cTnI did not change (<0.1 ng/mL) after DCCV at the measurement time points (one, three, and six hours). In addition, the value of cTnI remained constant (<0.1 ng/mL) in relation to the energy delivered, before DCCV and after DCCV (one, three, and six hours). However, it was found that there was a correlation between the outcome (AF reversion or not) and the energy used (joules). Synchronized DCCV with a biphasic defibrillator did not cause myocardial injury in any of the patients, as there was no change in cTnI values before and after DCCV.

Hospital Utilization and Mortality Post-electrical Cardioversion in Patients With Atrial Fibrillation in a Community Hospital.

Background Electrical cardioversion (EC) is a procedure that restores normal sinus rhythm in patients with atrial fibrillation (AF). Data on post-EC outcomes relative to the success of inpatient EC is limited. Methods This is a retrospective study of patients admitted for AF who underwent inpatient EC from January 1, 2017, to January 1, 2021. We collected demographics and clinical, biochemical, and echocardiographic parameters that impact the success of EC. Outcome events were 30-day readmissions and mortality. Results Our study included 54 unique patients who either had EC in the emergency room or as part of their hospital admission course for atrial fibrillation. Most patients were men with an average age of 70 years with traditional risk factors for cardiovascular disease including heart failure, coronary artery disease, and chronic kidney disease. The group who had unsuccessful cardioversion was older than those in the ineffective EC. Mortality at 30 days (p < 0.01), 1 year (p < 0.01), and 30-day readmission rate (p < 0.01) were higher in patients with unsuccessful EC. Conclusion A predictive model for successful EC remains difficult to establish. Patients with unsuccessful in-hospital EC are at high risk for mortality and readmissionat 30 days and require a comprehensive pre-discharge multidisciplinary approach and prioritized and individualized post-discharge integrated care.

Cavutilide (Refralon) for pharmacological cardioversion of early recurrence atrial fibrillation and flutter in blanking period after pulmonary veins isolation

Objective. Evaluate efficacy and safety of cavutilide (Refralon) for pharmacological cardioversion in patients with recurrent atrial fibrillation and flutter (AF/AFL), in 90days blanking period of catheter ablation.Materials and methods. included 56 patients: 46 patients with recurrent paroxysmal AF/AFL and 10 patients with recurrent persistent AF/AFL. In 45 patients (80.3%), sinus rhythm (SR) restoration was performed within 7 days from the moment of catheter ablation. Intraoperative confirmation of pulmonary vein (PV) isolation was noted in 85.7% cases (n=48). After excluding contraindications, cavutilide was administrated in the intensive care unit according to a 4-stage protocol (5 µg/kg – 5 µg/kg-10 µg/ kg – 10 µg/kg). Effectiveness of pharmacological cardioversion was assessed as the fact of restoring SR and the fact of preservation of SR 24 hours after cavutilide administration. Safety points – QT prolongation, ventricular arrhythmogenic effects, pauses and bradyarrhythmias.Results. The overall effectiveness of cavutilide among all included patients reached 98.2% (n=55), and preservation of SR 24 hours after cavutilide administration was observed in 94.5% (n=53) patients. All the patients with recurrent persistent AF/AFL successfully restored and maintained SR 24 hours after cavutilide administration 100% (n=10). In patients with recurrent paroxysmal AF/AFL restoration of SR observed in 97.8% (n=45) and preservation of SR after 24 hours – in 93.4% (n=43), respectively. The effectiveness of cavutilide did not depend on the results of the catheter ablation. Recurrences of AF/AFL after SR restoration were more common in patients without successful PV isolation. QT prolongation &gt;500ms observed in 8.9% (n=5) of cases, including 1 case of self-terminating torsade de pointes, managed by MgSO4 infusion. Bradyarrhythmias that did not require urgent therapy were noted in 10.7% (n=6) of cases.Conclusion. Pharmacological cardioversion with Cavutilide (Refralon) is highly effective and safe method of SR restoration in patients with recurrent AF/AFL in 90days blanking period after catheter ablation.

Digital patient care program following successful ablation or cardioversion of patients with atrial fibrillation

Abstract Background The current ESC guidelines on atrial fibrillation recommend the assessment of disease burden and the rigorous management of cardiovascular risk factors. A digital patient care program (Digital Health Program Atrial Fibrillation) was offered to patients following pulmonary vein isolation or cardioversion in cooperation with a major German statutory health insurer and a leading cardiology clinic. The 12 month program consists of the following functions: (1) self-recording of 1-channel-ECGs by patients with the possibility to receive short-term assessment by a teledoctor; (2) Patient education on health literacy, management of risk factors and lifestyle optimization via an App; (3) Monitoring of blood pressure and body weight; (4) Medication management via the App; und (5) videoconsultations on demand. When needed, medication was optimized by the teledoctors, or patients were referred to their family practice or cardiologists. Results an interim analysis of 72 patients that have participated in the first 6 months of the program showed: 1.) Over 20,000 ECGs were written, or a mean of approx. 1.5 ECGs/patient/day. Based on the teledoctor assessment of the ECGs and the videoconsultation over the platform recurring atrial fibrillation could be detected early and with high reliability, and patients could be advised. 2.) Figure A.: In patients with known, but insufficiently controlled arterial blood pressure at baseline (systolic blood pressure &amp;gt; 130 mmHg), blood pressure was reduced by 7.2 ±7.8 mmHg (mean ± std); n = 20. 3.) Figure B.: In obese patients at baseline (BMI ≥ 30) the body weight was reduced by 3.03 ±4.71 KG (mean ± std); n = 26. Summary: The combination self-recorded ECGs with high adherence, the feedback by the App and the possibility to book a short-term teledoctor appointment made it possible to perform quick and reliable assessment and give concrete recommendations to the patient. Furthermore, the accompanying education program led to reduced blood pressure and body weight. This systematic analysis of a real world digital patient care program indicates that the program is feasible and effective. These results need to be confirmed in a controlled study.Figure 1

Prediction of the success of electrical cardioversion in patients with atrial fibrillation using parameters obtained by spectral and vectorcardiographic analysis of the ECG

Abstract Introduction Electrical cardioversion (ECV) still presents a treatment option for atrial fibrillation (AF). Despite the great success rate in the acute setting, its long-term success rate is low. The aim of the study was to find predictors of SR maintenance after ECV using spectral and vectorcardiographic (VCG) analysis of the ECG curve. Methods Consecutive patients with AF referred for elective ECV were prospectively enrolled. The digital ECG recording obtained before the ECV was analyzed using spectral and VCG analysis. All patients had Holter monitoring and clinical follow-up three months after cardioversion to assess SR maintenance. Atrial fibrillation activity was analyzed by spectral analysis, determining the dominant frequency (DF), RI (regularity index) and OI (organization index). QRS complexes were analyzed by vectorcardiography and dXmean, dYmean and dZmean (derivation of VCG signals) parameters were determined. Using logistic regression (LR) with backward parameter reduction, separate and combined predictive models of SR maintenance were calculated based on both the analysis from the VCG data and the spectral analysis data. Additional models with a forward selection of clinical variables were also calculated. The efficiency of the models was evaluated on a separate test subset of the data (N=32). Results A total of 80 patients were enrolled (age 70+10 years, 48 (64%) men, CHADSVASc 3.17+1.5, BMI 29.75kg/m2). At the 3-month follow-up, AF recurrence was present in 36 patients (45%). Using only vectorcardiographic parameters, dXmean (OR 3.07, 95 %CI 1.14- 8.63), p=0.001) and dYmean (OR 0.26, 95% CI 0.09-0.72), p &amp;lt;0.001) best predicted the SR maintenance (AUC of 0.72). Using only spectral analysis parameters, the best predictor was DF (OR 3.07, 95%CI 1.14-8.63), p=0.012) with AUC of 0.66. By combining the results of spectral analysis and vectorcardiography, an AUC of 0.78 was achieved. Among the clinical parameters, the most significant predictors were insufficiently controlled arterial hypertension and previous history of stroke. Conclusion Digital analysis of ECG curves using deeper mathematical models provides a better predictive model than classical clinical and echocardiographic models. The combination of spectral analysis of fibrillation atrial activity and vectorocardiographic analysis of QRS complexes revealed more accurate predictive information compared to both analyses alone.

Biomarkers of fibrosis and inflammation and the risk of arrhythmia recurrence after elective electrical cardioversion in patients with atrial fibrillation and metabolic syndrome

Biomarkers of fibrosis and inflammation and the risk of arrhythmia recurrence after elective electrical cardioversion in patients with atrial fibrillation and metabolic syndrome

Functional tricuspid regurgitation and efficacy of electrical cardioversion in patients with atrial fibrillation and atrial functional mitral regurgitation.

Atrial functional mitral regurgitation (afMR) is common in patients with atrial fibrillation (AF). The presence of functional tricuspid regurgitation (fTR), which arises as a secondary effect of afMR, has the potential to impact the effectiveness of procedures aimed at restoring normal heart rhythm. In this study, we sought to evaluate the efficacy of electrical cardioversion (CVE) in AF regarding the presence and degree of fTR in patients with afMR. Retrospective analysis included 521 patients with persistent AF on optimal medical therapy undergoing CVE. 157 (30.1%) patients had afMR (characterized by left ventricle ejection fraction ≥ 50% and LA dilatation) and were divided into 2 groups: the group with fTR (107, 68.2%) and the group without fTR (50, 31.9%). Patients with afMR and fTR had a higher prevalence of metabolic syndrome (p = 0.02) and greater right atrial area (p < 0.01) compared to patients without fTR. The efficacy of CVE was lower in the group with fTR in comparison to patients with isolated afMR (82.2% vs. 94%; p = 0.048) and it was unrelated to the degree of fTR (p = 0.15) and RVSP (p = 0.56). The energy required for successful CVE was comparable regardless of the presence (p = 0.26) or severity of fTR (p = 0.94). The fTR frequently coexists with afMR and it significantly diminishes the effectiveness of CVE for treating AF. The degree of fTR does not appear to influence the efficacy of CVE.

Use of C-reactive protein for prediction of sinus rhythm maintenance after pharmacologic cardioversion in patients with Metabolic Syndrome

Abstract Background Approximately 50% of patients undergoing cardioversion present with a recurrence of Atrial Fibrillation ( AF) within 3–6 months of cardioversion despite ongoing antiarrhythmic treatment (AAD). Inflammation has been involved in the pathogenesis of both metabolic syndrome (MS) and atrial fibrillation. Evidence has indicated that inflammatory changes is essential for recurrence of AF. Therefore, identifying patients at high risk of AF recurrence remains challenging. Objective We tested the hypothesis: increased C-reactive protein (CRP) levels are associated with a greater risk of AF recurrence after pharmacologic cardioversion (PCV) Methods We conducted a multicenter observational cross-sectional study. 215 consecutive adult participants (≥18 and &lt;65years of age) were recruited with MS and symptomatic AF (paroxysmal and persistent). They were admitted at six general cardiology Health Care Clinics, underwent PCV, and during a one calendar year follow-up period, were stratified into two groups according to CRP levels (105 participants (50 females and 55 males) with level of CRP ≥3mg/L and 110 (58 females and 52 males) with level of CRP &lt;3mg/L). Recurrence of AF during follow-up period was defined as the study end-point. Results After the follow-up of one year, only (31.8%) of patients with MS and CRP levels above the cut-off of 3 mg/L remain in sinus rhythm, compared to (64. 7%) of patients with MS and CRP levels below the cut-off of 3 mg/L (p=0. 002). Conclusions CRP, an easily determined marker in everyday clinical practice, may provide significant prognostic information regarding sinus rhythm maintenance and could be useful for predicting the recurrence of AF after successful pharmacologic cardioversion in clinical practice.

Results of a prospective randomized study comparing efficacy and safety of refralon and amiodarone for cardioversion in patients with paroxysmal atrial fibrillation and flutter

Aim. To compare efficacy and safety of refralon and amiodarone for cardioversion in patients with paroxysmal atrial fibrillation and flutter (AF/AFL). Methods. The study included 60 patients (32 men and 28 women) with symptomatic paroxysmal AF/AFL. All patients underwent a preliminary examination to exclude contraindications to cardioversion. The procedure of pharmacological cardioversion was carried out in the intensive care unit. By the method of envelope randomization, patients were divided into equal groups of refralon and amiodarone, 30 participants each. Both groups did not differ significantly in terms of main clinical characteristics. Cardioversion with refralon consisted of four subsequent iv injections: 5-5 - 10-10 µg/kg of body weight at intervals of 15 minutes. Patients of the second group were intravenously administered amiodarone at a dose of 5 mg/kg of body weight for 20-60 minutes, depending on the tolerability of the drug. In case of AF/AFL maintaining after 60 minutes from the start of administration, the infusion of amiodarone 100 mg/h continued until restoration of sinus rhythm (SR) or until the maximal total dose of 1200 mg/day was reached. Patients were observed for 24 hours.Results. SR restored in 96.7% (29 of 30) of patients in the refralon group, of which 56.7% (17 of 30) - after a dose of 5 μg / kg. In the amiodarone group SR restored in 53.3% (16 of 30) patients (p&lt;0.001). Median time to arrhythmia conversion in refralon group was 14 [7;23] min, while in amiodarone group it was 150 [82;240] min (p&lt;0.001). Within 60 minutes SR was restored in 26 patients in group of refralon and only in 4 patients in group of amiodarone (p&lt;0.001). There were no statistically significant differences in the incidence of major adverse cardiac events, bradyarrhythmias, lowering of blood pressure, and QT prolongation between the groups.Conclusion. In randomized trial Refralon demonstrated higher rate of successful AF/AFL conversion and shorter time to SR restoration than amiodarone. The most of patients restored SR after administration of the lowest dose of refralon, that ensures the safety of cardioversion.

Efficacy and safety of modified Valsalva maneuver for treatment of paroxysmal supraventricular tachycardia: a meta-analysis.

To compare the efficacy and safety of the modified versus standard Valsalva maneuver in the treatment of paroxysmal supraventricular tachycardia (PSVT). The PubMed, Embase, Web of Science, CNKI, WanFang Data, and VIP electronic databases were searched to identify studies comparing the modified and standard Valsalva maneuvers in the treatment of PSVT from database inception to 1 May 2023. Two reviewers independently screened the literature, extracted the data, and assessed the risk of bias of all included studies. Nineteen randomized controlled trials involving 2527 patients with PSVT were included. The overall rate of cardioversion was higher in the modified than standard Valsalva group (risk ratio [RR] = 1.80, 95% confidence interval [CI] = 1.61-2.01), as was the success rate of cardioversion after a single Valsalva maneuver (RR = 2.05, 95% CI = 1.74-2.41). There was no statistically significant difference in adverse reactions between the two groups (RR = 1.07, 95% CI = 0.82-1.38). Current evidence suggests that the modified Valsalva maneuver can significantly improve the success rate of cardioversion in patients with PSVT without increasing adverse reactions. The modified Valsalva maneuver is therefore worth promoting and should be considered as a routine first treatment.INPLASY registration number: 2023100092.

Effectiveness of transoesophageal echocardiography guided direct current cardioversion in patients with atrial fibrillation

Effectiveness of transoesophageal echocardiography guided direct current cardioversion in patients with atrial fibrillation

In Situ Transesophageal Echocardiography During Electrical Cardioversion in Patients With Atrial Fibrillation—Safety and Echocardiographic Findings

Transesophageal echocardiography (TEE) can reliably detect left atrial (LA) and LA appendage (LAA) thrombus in patients with atrial fibrillation (AF) before electrical cardioversion (ECV). However, evaluating cardiac and valve function pre-ECV can be challenging due to the increased and irregular heart rate. Additionally, post-ECV atrial stunning increases the risk of LAA thrombosis. Therefore, post-ECV TEE may allow for useful appendage, ventricular, and valve function assessment. However, the safety and usefulness of leaving the TEE probe in situ during ECV for post-ECV cardiac evaluation in clinical practice have not been previously evaluated. We analyzed 37 out of 86 consecutive patients who had the TEE probe left in situ, for clinical reasons, during ECV by a single operator between February 20, 2019, and January 3, 2023. We examined changes in left ventricular (LV) function, dynamic changes in valvular regurgitation, electromechanical coupling of the left atrium, and qualitative spontaneous echo contrast. We also assessed the presence of any complications related to the periprocedural TEE exam. The mean age of the patients was 74±9.65years, and 29 (78%) were male. The periprocedural TEE time ranged from 7 to 55minutes, with an average of 20.78minutes. Immediately after ECV and restoration of normal sinus rhythm, there was an improvement in LV ejection fraction (47%±11.9% vs 40%±15.8%; P=.035). There was also a reduction in baseline mitral regurgitation of greater than moderate degree. However, spontaneous echo contrast worsened in the LAA in 11 (31.4%) patients. Additionally, 1 patient developed a new LAA thrombus, and 24 patients (72%) had evidence of electromechanical coupling with Doppler evidence of LA contraction. Clinically significant degenerative aortic and mitral stenosis were identified in 8% and mild or greater aortic regurgitation in 8% of patients post-ECV. No procedural complications were observed. In situ TEE before, during, and after ECV is safe and provides useful clinical information regarding immediate cardiac changes after ECV, with diagnostic and therapeutic implications.

Abstract 14165: Left Atrial Appendage Emptying Velocity as a Predictor of Energy Required for Successful DC Cardioversion in Patients With Atrial Fibrillation

Background: Atrial fibrillation (AF) is a prevalent cardiovascular disease in the elderly population. Restoring sinus rhythm in AF often involves antiarrhythmic drugs, direct current (DC) cardioversion, and ablation. The predictive value of left atrial appendage (LAA) emptying velocity in determining the energy required for successful DC cardioversion remains uncertain. Aim: To study the association between LAA emptying velocity and the amount of energy required for cardioversion in patients with AF undergoing DC cardioversion. Methods: A total of 79 consecutive AF patients were enrolled in the study. Transesophageal echocardiography was performed to exclude the presence of clot formation, after which patients underwent DC cardioversion using escalating biphasic energy levels of 100 joules, 200 joules, and 360 joules to restore sinus rhythm. Patients were stratified into two groups based on LAA emptying velocity: the low-velocity group (≤30 cm/sec) and the high-velocity group (&gt;30 cm/sec). Clinical characteristics were compared between the groups. Results: Of the 79 patients, 49 had a low LAA emptying velocity (LAAEV). The low-velocity group was older, with a mean age of 75 years compared to 70 years in the high-velocity group. The severity of mitral regurgitation was similar between the two groups. Patients with reduced LAA emptying velocity required significantly higher joules for successful cardioversion compared to the high-velocity group (192 joules vs. 155 joules, p-value = 0.02). Sleep apnea was more prevalent in the high-velocity group. The utilization of antiarrhythmic medications did not differ significantly between the groups (55% vs. 63%, p-value = 0.25). Conclusions: The study showed AF patients with low LAA emptying velocity require higher energy levels for successful cardioversion, suggesting that LAA emptying velocity may serve as a predictor of energy requirement in DC cardioversion for restoring sinus rhythm in AF patients.

Electric cardioversion in patients treated with oral anticoagulants: embolic material in the left atrial appendage.

Atrial fibrillation (AF) remains the most common arrhythmia. The sinus rhythm restoration procedure without adequate anticoagulant preparation may lead to a thromboembolic event in approximately 5-7% of patients. The initiation of oral anticoagulation significantly reduces this risk by inhibiting formation of embolic material in the heart cavities, especially in the left atrial appendage (LAA). However, there is a group of patients who develop embolic material in the LAA despite oral anticoagulation treatment. The best treatment method to dissolve thrombus in the LAA is not clear, due to the lack of studies with adequate power and endpoints that can determine the best management strategy. We present clinical trials comparing the efficacy and safety of oral anticoagulants in patients undergoing AF cardioversion. We evaluate the frequency of LAA thrombus formation in patients with AF on treatment with oral anticoagulants. Furthermore, we discuss the effectiveness of various treatment strategies on LAA thrombus resolution.

Is transesophageal echocardiography necessary before electrical cardioversion in patients treated with non-vitamin K antagonist oral anticoagulants? Current evidence and practical approach.

According to current guidelines, non-vitamin K antagonist oral anticoagulants (NOACs) should be used at least 3 weeks before planned electrical cardioversion. In accordance with international atrial fibrillation (AF) guidelines, transesophageal echocardiography (TEE) is a pre-procedural examination recommended as an alternative to adequate oral anticoagulation. The strategy related to qualifying patients treated with NOACs for pre-procedural TEE differs in individual centers. Therefore, it is necessary to create an algorithm that will standardize estimation of left atrial appendage thrombus (LAAT) prevalence risk and thereby qualify NOAC-treated patients to TEE in the most effective way. We assessed the available studies on LAAT predictors. Risk factors for LAAT formation are not necessarily the same as the risk factors for thromboembolic events in patients with AF. The main risk factor for LAAT are as follows: previous intracardiac thrombus, irregular use of NOAC, inappropriate dose reduction of NOAC, previous stroke, CHA2DS2-VASc score ≥ 3 points, glomerular filtration rate < 60 mL/min/1.73 m², reduced left ventricular ejection fraction, or left atrial enlargement. Based on available evidence, we proposed algorithm guarantees more systematic approach to performing TEE in patients undergoing electrical cardioversion.